Blab Business
Canopy Growth Reports Narrowed Loss, Double-Digit Revenue Growth Amid MTL Acquisition and Recapitalization
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) revealed on Monday that its fiscal fourth‑quarter loss narrowed to an adjusted $0.29 per share, a 71% improvement over the $1.01 loss reported a year earlier. The Canadian cannabis producer also posted a 13.6% rise in quarterly revenue to $51.95 million, though the figure fell short of analyst expectations. The company said the turnaround was driven by the completion of its acquisition of MTL Cannabis and a strategic recapitalization that strengthened its balance sheet.
Canopy’s full‑year results, covering the period ended March 31, 2026, showed net revenue growth of 20% in its Canada adult‑use segment and 18% in the Canada medical segment. The company’s net cash position at year‑end rose to $131.3 million after a January 2026 recapitalization that included a US$150 million term loan and a conversion of existing convertible debentures into new debt, cash, shares and warrants. The recapitalization extended the maturity of all outstanding debt to at least January 2031.
The acquisition of MTL Cannabis, completed during the fiscal year, positioned Canopy as Canada’s leading medical cannabis company by revenue. MTL’s trailing‑twelve‑month revenue was reported at $84 million, with gross margins above 50% before fair‑value adjustments and an operating cash flow of $11 million. The deal also expanded Canopy’s cultivation footprint in Quebec, the country’s second‑largest cannabis market.
CEO Luc Mongeau said the year was used to reset operations and lay groundwork for expansion, with Europe identified as a key target market. “As the leading medical cannabis business in Canada by revenue, we are well positioned to extend that leadership into Europe,” Mongeau said, describing the region as representing “enormous long‑term opportunity.” CFO Tom Stewart highlighted the balance‑sheet improvements as a risk‑reduction measure that also expands the company’s strategic options.
Canopy expects net revenue growth across the business in fiscal 2027 and projects that improvements in cultivation practices will contribute to meaningful gross‑margin gains. The company is targeting positive adjusted EBITDA for the fiscal year, though it cautioned that MTL integration activities in the first half of the year will mean stronger year‑over‑year improvements are expected in the second half.
The results come at a time when the Canadian cannabis market is consolidating. Canopy’s acquisition of MTL and its recapitalization are part of a broader strategy to strengthen its position in the medical segment while preparing for international expansion. The company’s net cash balance and extended debt maturities provide a cushion for further acquisitions or organic growth.
Investors will watch the company’s upcoming earnings release for fiscal 2027, where guidance on revenue growth, gross‑margin improvement, and EBITDA will be critical. The company’s focus on Europe, combined with its strengthened balance sheet, may influence its capital allocation decisions and potential future acquisitions in the international market.
In summary, Canopy Growth’s latest financials show a narrowed loss and double‑digit revenue growth, driven by the MTL acquisition and a recapitalization that bolstered its cash position. The company is positioning itself for continued growth in Canada’s medical cannabis market and is targeting expansion into Europe, with a focus on improving gross margins and achieving positive adjusted EBITDA in the next fiscal year.
Canopy’s full‑year results, covering the period ended March 31, 2026, showed net revenue growth of 20% in its Canada adult‑use segment and 18% in the Canada medical segment. The company’s net cash position at year‑end rose to $131.3 million after a January 2026 recapitalization that included a US$150 million term loan and a conversion of existing convertible debentures into new debt, cash, shares and warrants. The recapitalization extended the maturity of all outstanding debt to at least January 2031.
The acquisition of MTL Cannabis, completed during the fiscal year, positioned Canopy as Canada’s leading medical cannabis company by revenue. MTL’s trailing‑twelve‑month revenue was reported at $84 million, with gross margins above 50% before fair‑value adjustments and an operating cash flow of $11 million. The deal also expanded Canopy’s cultivation footprint in Quebec, the country’s second‑largest cannabis market.
CEO Luc Mongeau said the year was used to reset operations and lay groundwork for expansion, with Europe identified as a key target market. “As the leading medical cannabis business in Canada by revenue, we are well positioned to extend that leadership into Europe,” Mongeau said, describing the region as representing “enormous long‑term opportunity.” CFO Tom Stewart highlighted the balance‑sheet improvements as a risk‑reduction measure that also expands the company’s strategic options.
Canopy expects net revenue growth across the business in fiscal 2027 and projects that improvements in cultivation practices will contribute to meaningful gross‑margin gains. The company is targeting positive adjusted EBITDA for the fiscal year, though it cautioned that MTL integration activities in the first half of the year will mean stronger year‑over‑year improvements are expected in the second half.
The results come at a time when the Canadian cannabis market is consolidating. Canopy’s acquisition of MTL and its recapitalization are part of a broader strategy to strengthen its position in the medical segment while preparing for international expansion. The company’s net cash balance and extended debt maturities provide a cushion for further acquisitions or organic growth.
Investors will watch the company’s upcoming earnings release for fiscal 2027, where guidance on revenue growth, gross‑margin improvement, and EBITDA will be critical. The company’s focus on Europe, combined with its strengthened balance sheet, may influence its capital allocation decisions and potential future acquisitions in the international market.
In summary, Canopy Growth’s latest financials show a narrowed loss and double‑digit revenue growth, driven by the MTL acquisition and a recapitalization that bolstered its cash position. The company is positioning itself for continued growth in Canada’s medical cannabis market and is targeting expansion into Europe, with a focus on improving gross margins and achieving positive adjusted EBITDA in the next fiscal year.
